Livnat Jerby is an Assistant Professor in the Department of Genetics at Stanford University. Dr. Jerby develops multidisciplinary engineering-based systems to uncover molecular mechanisms governing immune recognition and function and design new immunomodulating and tissue remodeling interventions for cancer treatment and prevention. As a postdoctoral fellow in Aviv Regev’s lab at the Broad Institute of MIT and Harvard, Dr. Jerby identified new mechanisms controlling cellular and tissue immunogenicity and demonstrated the potential of epigenetic reprogramming as a therapeutic modality to overcome immunotherapy resistance in cancer. Dr. Jerby holds a B.Sc. in Computer Science and Biology and obtained her PhD in 2016 from Tel Aviv University, where she worked with Prof. Eytan Ruppin, studying genetic interactions in cancer. In November 2020 she joined Stanford Genetics to establish her own lab. Bringing together latest advances in genetic engineering, machine learning, and single-cell/in situ sequencing her laboratory develops scalable systems to study and reprogram cellular circuits at greater scale, resolution, and depth, and leverage both innate and adaptive immunity to eliminate ovarian cancer cells in an antigen-dependent and -independent manner. Her research has been generously supported by the Rothschild Foundation, the Schmidt Family Foundation, the Cancer Research Institute (CRI), the Burroughs Wellcome Fund (BWF), Paul G. Allen Family Foundation, and Chan Zuckerberg Biohub initiative.